On September 25, Moderna, Inc. rose 3.53% in regular trading, trading at $201.44/share, with turnover of $1.495 billion, extending its breakout above the $200 level to fresh 52-week highs.

On the news front, Moderna recently announced that three research abstracts on its personalized mRNA cancer vaccine intismeran autogene have been accepted at the European Society for Medical Oncology annual meeting. Most notably, the complete Phase 3 INTerpath-001 trial data on melanoma will be formally presented on October 24 in the Presidential Symposium — the highest-profile slot at the conference. Two additional abstracts will disclose clinical data on the vaccine's application in pancreatic cancer and early-stage non-small cell lung cancer.

Options market activity has reinforced the bullish tone. A $3.225 million bull call spread targeting the $190–$270 range through March 2027 was recorded, with no offsetting bearish large-block trades observed. This follows a separate $9.18 million deep in-the-money call purchase earlier in the week. Since the Phase 3 clinical success was announced in August, Moderna shares have surged more than fivefold year-to-date.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)